12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Portfolio Pulse from Benzinga Insights
In Tuesday's pre-market session, several healthcare stocks experienced significant movements. SILO Pharma, TRACON Pharma, Fresh2 Group, Brainstorm Cell, TC BioPharm, and Connect Biopharma Hldgs saw their shares rise by 36.2%, 30.02%, 28.4%, 22.03%, 19.23%, and 17.47%, respectively. On the other hand, MorphoSys, Alzamend Neuro, Enzo Biochem, Cardio Diagnostics Hldgs, Sharps Technology, and Nemaura Medical saw their shares fall by 24.1%, 13.67%, 13.39%, 12.22%, 11.91%, and 10.17%, respectively. MorphoSys's drop is attributed to their Q3 earnings released 4 days ago.
November 21, 2023 | 1:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Fresh2 Group shares climbed 28.4% to $1.22, with a market value of $17.9 million.
The notable pre-market increase could lead to continued upward momentum in the short term.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 90
POSITIVE IMPACT
SILO Pharma shares surged 36.2% in pre-market trading with a market cap of $6.9 million.
The significant pre-market gain suggests positive investor sentiment, which could lead to a short-term price increase.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 90
POSITIVE IMPACT
TRACON Pharma shares increased by 30.02% to $0.23 with a market cap of $7.0 million.
The substantial pre-market rise indicates a positive market reaction, potentially leading to further short-term gains.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 90
NEGATIVE IMPACT
Alzamend Neuro shares declined by 13.67% to $1.2, with a market value of $7.7 million.
The pre-market decrease may indicate negative sentiment, potentially leading to a short-term downtrend.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 80
NEGATIVE IMPACT
Enzo Biochem stock fell 13.39% to $1.1, with a market value of $55.5 million.
The pre-market drop may reflect investor concerns, possibly affecting the stock negatively in the short term.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 80
NEGATIVE IMPACT
MorphoSys shares fell 24.1% to $4.45, with a market value of $608.2 million, following Q3 earnings.
The decline is directly related to the market's reaction to the Q3 earnings report, suggesting a negative short-term impact.
CONFIDENCE 85
IMPORTANCE 85
RELEVANCE 95